Please check your internet connection and try again.
## Ecospirin (Aspirin, Enteric-Coated)
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay absorption and reduce gastric irritation.
### Primary Indications
* Pain and inflammation (mild to moderate)
* Fever
* Prevention of cardiovascular events (e.g., myocardial infarction, stroke) in patients at risk.
* Kawasaki disease (adjunctive therapy).
### Adult Dosing
* **Pain and Fever:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum dose: 4000 mg per day.
* **Cardiovascular Prevention (Secondary):** 75 mg to 100 mg once daily. Doses may vary based on specific guidelines and physician discretion.
* **Cardiovascular Prevention (Primary):** Dosing is controversial and typically reserved for select high-risk individuals. Consult current guidelines. 75 mg to 100 mg once daily is often used.
* **Kawasaki Disease:** Doses vary significantly depending on the phase of illness and presence of coronary artery abnormalities. Initial high-dose therapy followed by low-dose maintenance is common. Consult specific pediatric cardiology protocols.
### Pediatric Dosing
* **Pain and Fever:** Dosing is typically weight-based. Commonly: 10-15 mg/kg/dose every 4-6 hours. Maximum dose: 650 mg/dose or 4000 mg/day. **Use is generally discouraged in children and adolescents (<19 years) due to the risk of Reye's syndrome, especially during viral illnesses.**
* **Kawasaki Disease:** See adult dosing; specific protocols are essential.
### Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary in severe impairment.
* **Hepatic Impairment:** Use with caution. Monitor liver function.
### Contraindications
* Hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Active peptic ulcer disease.
* Bleeding disorders.
* Asthma precipitated by NSAIDs.
* Severe hepatic or renal impairment.
* Concurrent use of methotrexate (high dose).
* Children and adolescents with viral infections (due to Reye's syndrome risk).
### Adverse Effects
* **Common:** Gastrointestinal upset, dyspepsia, heartburn, nausea.
* **Serious:** Gastrointestinal bleeding, ulceration, perforation, tinnitus, hearing loss, bronchospasm, hypersensitivity reactions, Reye's syndrome (in children/adolescents with viral illness), exacerbation of asthma.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and Salicylates:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **SSRIs and SNRIs:** Increased risk of bleeding, particularly GI bleeding.
* **Alcohol:** Increased risk of GI irritation and bleeding.
* **Uricosuric agents (e.g., probenecid):** Decreased efficacy of uricosuric agent.
* **Methotrexate:** Increased methotrexate toxicity.
### Monitoring
* Signs and symptoms of GI bleeding (e.g., melena, hematemesis, abdominal pain).
* Tinnitus or hearing changes.
* Renal function, especially in elderly or renally impaired patients.
* Liver function.
* Platelet function (if clinically indicated).
### Clinical Pearls
* The enteric coating delays absorption and reduces gastric irritation but does not eliminate the risk of GI bleeding. Do not crush or chew enteric-coated tablets.
* Discontinue aspirin at least 5-7 days before elective surgery due to its irreversible antiplatelet effect.
* Aspirin should be used with extreme caution, if at all, in children and adolescents due to the risk of Reye's syndrome. Acetaminophen or ibuprofen are generally preferred for pain and fever in this population when appropriate.
***
*This information is intended for healthcare professionals. Please refer to the official prescribing information for the most up-to-date and complete details.*
